334 related articles for article (PubMed ID: 21709130)
21. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
Axlund SD; Lambert JR; Nordeen SK
Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
[TBL] [Abstract][Full Text] [Related]
22. Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti J; Sharp A; Brooks N; Yuan W; McNair C; Chand SN; Pal A; Figueiredo I; Riisnaes R; Gurel B; Rekowski J; Bogdan D; West W; Young B; Raja M; Prosser A; Lane J; Thomson S; Worthington J; Onions S; Shannon J; Paoletta S; Brown R; Smyth D; Harbottle GW; Gil VS; Miranda S; Crespo M; Ferreira A; Pereira R; Tunariu N; Carreira S; Neeb AJ; Ning J; Swain A; Taddei D; ; Schiewer MJ; Knudsen KE; Pegg N; de Bono JS
Cancer Discov; 2021 May; 11(5):1118-1137. PubMed ID: 33431496
[TBL] [Abstract][Full Text] [Related]
23. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.
Gao XN; Lin J; Ning QY; Gao L; Yao YS; Zhou JH; Li YH; Wang LL; Yu L
PLoS One; 2013; 8(2):e55481. PubMed ID: 23390536
[TBL] [Abstract][Full Text] [Related]
24. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells.
Yan G; Eller MS; Elm C; Larocca CA; Ryu B; Panova IP; Dancy BM; Bowers EM; Meyers D; Lareau L; Cole PA; Taverna SD; Alani RM
J Invest Dermatol; 2013 Oct; 133(10):2444-2452. PubMed ID: 23698071
[TBL] [Abstract][Full Text] [Related]
25. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
[TBL] [Abstract][Full Text] [Related]
26. Acetyltransferases CBP/p300 Control Transcriptional Switch of β-Catenin and Stat1 Promoting Osteoblast Differentiation.
Zhang L; Zhu K; Xu J; Chen X; Sheng C; Zhang D; Yang Y; Sun L; Zhao H; Wang X; Tao B; Zhou L; Liu J
J Bone Miner Res; 2023 Dec; 38(12):1885-1899. PubMed ID: 37850815
[TBL] [Abstract][Full Text] [Related]
27. FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Caligiuri M; Williams GL; Castro J; Battalagine L; Wilker E; Yao L; Schiller S; Toms A; Li P; Pardo E; Graves B; Azofeifa J; Chicas A; Herbertz T; Lai M; Basken J; Wood KW; Xu Q; Guichard SM
Target Oncol; 2023 Mar; 18(2):269-285. PubMed ID: 36826464
[TBL] [Abstract][Full Text] [Related]
28. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
[TBL] [Abstract][Full Text] [Related]
29. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
[TBL] [Abstract][Full Text] [Related]
30. Regulation of insulin gene transcription by multiple histone acetyltransferases.
Sampley ML; Ozcan S
DNA Cell Biol; 2012 Jan; 31(1):8-14. PubMed ID: 21774670
[TBL] [Abstract][Full Text] [Related]
31. Combination Targeting of the Bromodomain and Acetyltransferase Active Site of p300/CBP.
Zucconi BE; Makofske JL; Meyers DJ; Hwang Y; Wu M; Kuroda MI; Cole PA
Biochemistry; 2019 Apr; 58(16):2133-2143. PubMed ID: 30924641
[TBL] [Abstract][Full Text] [Related]
32. Individual functions of the histone acetyl transferases CBP and p300 in regulating the inflammatory response of synovial fibroblasts.
Krošel M; Gabathuler M; Maciukiewicz M; Moser L; Lee GI; Marks M; Tomšič M; Distler O; Ospelt C; Klein K
J Autoimmun; 2021 Sep; 123():102709. PubMed ID: 34304080
[TBL] [Abstract][Full Text] [Related]
33. Inflammation-mediated abrogation of androgen signaling: an in vitro model of prostate cell inflammation.
Debelec-Butuner B; Alapinar C; Varisli L; Erbaykent-Tepedelen B; Hamid SM; Gonen-Korkmaz C; Korkmaz KS
Mol Carcinog; 2014 Feb; 53(2):85-97. PubMed ID: 22911881
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets.
Narayanan BA; Narayanan NK; Re GG; Nixon DW
Int J Cancer; 2003 Mar; 104(2):204-12. PubMed ID: 12569576
[TBL] [Abstract][Full Text] [Related]
35. Transcriptional activation of human matrix metalloproteinase-9 gene expression by multiple co-activators.
Zhao X; Benveniste EN
J Mol Biol; 2008 Nov; 383(5):945-56. PubMed ID: 18790699
[TBL] [Abstract][Full Text] [Related]
36. E2A proteins enhance the histone acetyltransferase activity of the transcriptional co-activators CBP and p300.
Hyndman BD; Thompson P; Bayly R; Côté GP; LeBrun DP
Biochim Biophys Acta; 2012 May; 1819(5):446-53. PubMed ID: 22387215
[TBL] [Abstract][Full Text] [Related]
37. Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells.
Heemers HV; Schmidt LJ; Kidd E; Raclaw KA; Regan KM; Tindall DJ
Prostate; 2010 Jun; 70(9):959-70. PubMed ID: 20166126
[TBL] [Abstract][Full Text] [Related]
38. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
39. The histone acetyltransferase p300 inhibitor C646 reduces pro-inflammatory gene expression and inhibits histone deacetylases.
van den Bosch T; Boichenko A; Leus NGJ; Ourailidou ME; Wapenaar H; Rotili D; Mai A; Imhof A; Bischoff R; Haisma HJ; Dekker FJ
Biochem Pharmacol; 2016 Feb; 102():130-140. PubMed ID: 26718586
[TBL] [Abstract][Full Text] [Related]
40. Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells.
Huang EC; Zhao Y; Chen G; Baek SJ; McEntee MF; Minkin S; Biggerstaff JP; Whelan J
BMC Complement Altern Med; 2014 Feb; 14():68. PubMed ID: 24555771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
